Hummingbird Bioscience Started Phase II Drug Trials
The company launched clinical testing for a potential chemo-free cancer treatment in four countries.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Do you trust artificial intelligence to play a central role in the discovery of new medicines?
Hummingbird Bioscience has officially commenced Phase II clinical trials for its drug candidate HMBD-001. The study is currently evaluating the medication in combination with cetuximab for patients with advanced squamous cell cancers.
Why it matters
The study targets HER3 and EGFR signaling pathways, which are critical for tumor cell proliferation in squamous cell carcinomas. By combining these therapies, the trial aims to offer an effective chemo-free alternative for patients with these aggressive cancer types.
The clinical trial HMBD-001-103 evaluates the combination of HMBD-001 with the EGFR inhibitor cetuximab. The treatment design specifically targets HER3 and EGFR signaling pathways identified as drivers of tumor growth.
The players
Hummingbird Bioscience
This biotechnology company focuses on developing precision therapies using its proprietary AIMM platform.
Merck KGaA
This multinational science and technology company is providing cetuximab for use in the clinical trial collaboration.
U.S. Food and Drug Administration
This federal agency is responsible for protecting public health by regulating the safety and efficacy of medical products.
The details
The trial is actively enrolling participants across China, Australia, Moldova, and Singapore to test the combination therapy. Researchers plan to utilize the proprietary AIMM platform to enrich the patient population throughout the study duration.
Timeline
September 30, 2026: Hummingbird Bioscience announced the initiation of Phase II trials.
The Tech Race
The use of the AIMM platform as a drug discovery tool is specific to the development of precision medicines by Hummingbird Bioscience. The current trial extends the application of the AIMM platform from initial discovery into the active clinical testing phase for patient selection.
For patients with advanced squamous cell cancers, this trial offers potential access to experimental treatments that focus on targeted pathways rather than traditional chemotherapy. The study outcome will determine if this combination becomes a viable future standard of care.
The takeaway
This trial represents a shift toward targeted oncology treatments that avoid the systemic toxicity of conventional chemotherapy. Future results will clarify whether dual-pathway inhibition can significantly improve outcomes for patients with treatment-resistant cancers.
Further reading
Find more clinical updates in the Biotech section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust artificial intelligence to play a central role in the discovery of new medicines?
